GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Hogge Precision, a leading provider of high-precision manufacturing solutions, today highlighted its advanced medical CNC ...

Nearly 150 new Florida laws went into effect July 1 and some of them make big changes you need to know. Here's the list.

Ecnoglutide is a glucagon-like peptide-1 (GLP-1 ... Unlike semaglutide, ecnoglutide preferentially targets the production of cyclic adenosine monophosphate, a messenger molecule associated with ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

Obesity costs U.S. health care nearly $173 billion yearly. With more than 200 related complications such as heart disease, ...

Amphastar Pharmaceuticals' first quarter results saw revenue remain flat compared to last year and fall slightly short of Wall Street’s projections, while non-GAAP earnings per share came in above ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug ...